Skip to content
OpenCapital
Get started

ANI Pharmaceuticals ANIP Operating Income

Operating Income at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$141.77M+41.3%
Viatris logo
ViatrisVTRS
-$79.7M+97.2%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$34.64M-25.8%
ALN
Alnylam PharmaceuticalsALNY
$268.64M+1,386%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$41.42M+89.6%
Amgen logo
AmgenAMGN
$2.67B+126%

Segments

By segment

See full
Generics and Other$40.32M-16.9%
Rare Disease and Brands$36.25M+71.5%

Other financials

Income statement

See full
Revenue$237.5M+20.5%
Gross profit$143.9M+16.0%
Net income$29.5M+88.1%
EPS (diluted)$1.28+85.5%

Balance sheet

See full
Cash & equivalents$311.2M+108%
Total debt$305.3M-3.5%
Total equity$562.3M+34.3%
Total assets$1.4B+10.0%

Cash flow

See full
Operating cash flow$58.4M+66.8%
CapEx$6.1M+146%
Free cash flow$52.3M+60.8%

Valuation

See full
Market cap$1.89B+18.3%
Enterprise value$1.88B+5.8%
P/E20.5×—
P/S2×-0.3×

Profitability

See full
Gross margin60.8%+1.5pp
Operating margin13.4%—
Net margin10%+8.1pp
FCF margin20.7%+10.8pp

Returns & leverage

See full
Return on equity18.8%+15.6pp
Debt / equity0.5×-0.2×
Current ratio3.1×+0.5×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ANI Pharmaceuticals's operating income?
ANI Pharmaceuticals (ANIP) reported operating income of $38.89M in Q1 2026.
How has ANI Pharmaceuticals's operating income changed year-over-year?
ANI Pharmaceuticals's operating income increased by 48.5% year-over-year, from $26.19M to $38.89M.
What is the long-term trend for ANI Pharmaceuticals's operating income?
Over 3 years (2021 to 2025), ANI Pharmaceuticals's operating income has grown at a 40.8% compound annual growth rate (CAGR), from -$39.79M to $111.09M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.